Geron cuts out companion diagnostics
This article was originally published in Clinica
Executive Summary
Geron has eliminated its companion diagnostic and drug discovery research programs, and reduced its work force by another 20 employees. Now the company's path forward depends solely on the results of an investigator-sponsored study for its lone drug candidate imetelstat in a single hematological indication.